AstraZeneca is global innovation-driven biopharmaceutical company specialising in the discovery, development, manufacturing and marketing of prescription medicines that make a meaningful difference in healthcare. AstraZeneca discovers new medicines that are designed to improve the health and quality of life of patients around the world - medicines which are innovative, effective and which offer added benefits such as reduced side effects or better ways of taking the treatment. They also focus on getting the best from every medicine they make by exploring all the ways it can be used or improved. Their business strategy sets out their path to success in delivering great medicines to patients through innovative science and global excellence in development and commercialisation.
Company Growth (employees)
Cambridge, GB
Size (employees)
59,700 (est)
AstraZeneca was founded in 1999 and is headquartered in Cambridge, GB

Key People/Management at AstraZeneca

Pascal Soriot

Pascal Soriot

Executive Director and Chief Executive Officer
Marc Dunoyer

Marc Dunoyer

Herren Wu

Herren Wu

Bahija Jallal

Bahija Jallal

Executive Vice President
Menelas Pangalos

Menelas Pangalos

Executive Vice President
Mark Mallon

Mark Mallon

Executive Vice President
Jeff Pott

Jeff Pott

General Counsel
Katarina Ageborg

Katarina Ageborg

Chief Compliance Officer
Caroline Hempstead

Caroline Hempstead

Executive Vice President, Human Resources and Corporate Affairs (interim)
Pam Cheng

Pam Cheng

Executive Vice-President
Fiona Cicconi

Fiona Cicconi

Executive Vice-President, Human Resources

AstraZeneca Office Locations

AstraZeneca has offices in Cambridge, London, Bangalore, Hong Kong and in 166 other locations
Wedel, DE
Wedel, Tinsdaler Weg 183
Wilmington, US
1800 Concord Pike, P.O. Box 15437
Osaka, JP
Grand Front Osaka Tower B, 3-1, Ofuka-cho, Kita-ku
Shanghai, CN
43/F CITIC Square, 1168 Nan Jing Xi Road
Hong Kong, HK
18/F, Shui On Centre, 6-8 Harbour Road, Wanchai
Bangalore, IN
Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road
Show all (171)

AstraZeneca Financials and Metrics

AstraZeneca Financials

AstraZeneca's revenue was reported to be $21.3 b in FY, 2016 which is a 10% decrease from the previous period.

Revenue (FY, 2016)

21.3 b

Revenue growth (FY, 2015 - FY, 2016), %


Gross profit (FY, 2016)

17.2 b

Gross profit margin (FY, 2016), %


Net income (FY, 2016)

3.4 b

Market capitalization (31-Oct-2017)

87.4 b

Closing share price (31-Oct-2017)


Cash (31-Dec-2016)

3.9 b
AstraZeneca's current market capitalization is $87.4 b.
USDFY, 2013FY, 2014FY, 2015FY, 2016


25.7 b26.1 b23.6 b21.3 b

Revenue growth, %


Cost of goods sold

5.3 b5.8 b4.6 b4.1 b

Gross profit

20.5 b20.3 b19 b17.2 b
GBPFY, 2013FY, 2014FY, 2015FY, 2016


6.1 b4.7 b4.6 b3.9 b

Accounts Receivable

3.6 b3.5 b3.4 b2 b

Current Assets

13.2 b12.2 b11.7 b10.1 b


6.4 b7 b7.2 b8 b
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash From Operating Activities

7.4 b7.1 b3.3 b4.1 b

Cash From Financing Activities

(2 b)(2 b)649.3 m1.7 b

Income Taxes Paid

(457.7 m)(8.1 m)(179.7 m)(113.1 m)
Y, 2016

Financial Leverage

4.2 x
Show all financial metrics

AstraZeneca Operating Metrics

FY, 2013FY, 2014FY, 2015FY, 2016

Phase I Trials




Phase II Trials


Projects in R&D Pipeline

Show all operating metrics

AstraZeneca Market Value History

AstraZeneca Revenue Breakdown

AstraZeneca Median Salaries

Source: 105 public H-1B filings from AstraZeneca

AstraZeneca's Web-traffic and Trends

AstraZeneca Online and Social Media Presence

AstraZeneca News and Updates

Future Growth of Performance Enhancing Drugs Market with Continuously Growing CAGR by 4.8% by 2023

Market Research Future published a half-cooked research report on global performance enhancing drugs market. Which is Expected to Grow at a CAGR over 4.8% from 2017 to 2023 Posted via Industry Today. Follow us on Twitter @IndustryToday

J&J, Lilly and AZ diabetes medications get another helping of real-world heart benefits

Last year, real-world data showed that SGLT2 diabetes medications could significantly cut heart failure hospitalizations and all-cause deaths. And now, a new analysis shows that they can also cut the rate of major cardiovascular events in patients new to treatment.

'Glowing' NEJM editorial highlights off-label potential for AstraZeneca's Imfinzi

AstraZeneca has had trouble easing concerns about its immuno-oncology portfolio, but a new editorial in the New England Journal of Medicine should do just that, one analyst says.

AstraZeneca goes to battle with GSK with nod for Nucala challenger Fasenra

AstraZeneca is about to find out whether its third-to-market respiratory biologic can stand out from the crowd—and a lower price might just do it. Fasenra, known in the clinic as benralizumab, won FDA approval for a severe type of asthma, and AZ is undercutting its two chief rivals.

AstraZeneca, Merck, Clovis and Tesaro, all vying for share, may all win on faster PARP growth

Ovarian cancer treatment has changed dramatically, and with several new drugs now duking it out in that market, the battle for share is changing, too. If recent numbers—and a new doctor survey—are any indication, Tesaro's Zejula is in the lead. But that could change.

Can AstraZeneca afford its fervent commitment to paying a high dividend?

AstraZeneca CEO Pascal Soriot committed to paying a generous dividend "today, tomorrow, and thereafter," during yesterday's earnings call. But investors can be tough on pharma companies when they fail to live up to such vows, and AZ will face some challenges coming up with the cash to fund its divid…
Show more

AstraZeneca Company Life and Culture

You may also be interested in